Overview

Safety and Efficacy of Deucravacitinib in Participants With Moderate to Severe Ulcerative Colitis

Status:
Active, not recruiting
Trial end date:
2023-04-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of oral deucravacitinib in participants with moderate to severe ulcerative colitis (UC).
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
BMS-986165